Effects of Docosahexaenoic Acid (DHA) on Cardiovascular Disease on Diabetic Patients

May 23, 2019 updated by: Hospices Civils de Lyon

Intake of Low Dose of Docosahexaenoic Acid: Effects on Platelet Functions and Redox Status in Diabetic Patients

Aim: to determine the effects of DHA supplementation:

  • on the platelet function through their aggregation and the pathway of arachidonic acid metabolism
  • on redox status on cells and plasma
  • on inflammation in 16 type 2 diabetic patients in a cross-over study comparing DHA (400 mg/day for 2 weeks) vs Sunflower oil (placebo). Each period is separated by a wash-out period of 6 to 9 weeks.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Bron, France
        • Hospices Civils de Lyon
      • Pierre-benite, France
        • Centre de Recherche en Nutrition Humaine (CRNH) Rhône-Alpes

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

55 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • woman
  • Type 2 diabetes
  • Menopausal or aged between 55 and 75 years old
  • Recent HbA1c between 6.5-10%
  • Oral anti-diabetic drugs or insulin therapy
  • Hypertension or antihypertensive drug

Exclusion Criteria:

  • Tobacco
  • Excessive drinking
  • Post-menopausal hormonal treatment
  • Treatment by acetylsalicylic acid, clopidogrel, gliclazide, ticlopidine, NSAID
  • Secondary cardiovascular prevention
  • antioxidant using
  • Fish intake >2 times a week
  • Anemia <10g/L
  • Thrombopenia <110g/L
  • Creatinine clearance <30 ml/min and/or proteinuria >1g/L

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DHA - Sunflower oil
400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
Dietary supplement: First period DHA
400 mg DHA supplementation by day for 2 weeks during the first study period
Experimental: Sunflower oil - DHA
Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
Dietary supplement: Second period DHA
400 mg DHA supplementation by day for 2 weeks during the second study period

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Platelet function induced by collagen
Time Frame: 4 blood sampling in 10 to 13 weeks

4 blood sampling are made during the time of study which expand from 10 weeks (washout period of 6 weeks) to 13 weeks (washout period of 9 weeks):

  • first at the beginning of the first period
  • second at the end of the period (2 weeks after beginning)
  • third at the beginning of the second period
  • fourth at the end of the period (2 weeks after beginning)
4 blood sampling in 10 to 13 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of cellular and plasmatic redox status
Time Frame: 4 blood sampling in 10 to 13 weeks

blood sampling are made during the time of study which expand from 10 weeks (washout period of 6 weeks) to 13 weeks (washout period of 9 weeks):

first at the beginning of the first period second at the end of the period (2 weeks after beginning) third at the beginning of the second period fourth at the end of the period (2 weeks after beginning)
4 blood sampling in 10 to 13 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hospices Civils de Lyon

Investigators

  • Principal Investigator: Martine LAVILLE, MD, PhD, Hospices Civils de Lyon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2010

Primary Completion (Actual)

February 1, 2013

Study Completion (Actual)

February 1, 2013

Study Registration Dates

First Submitted

June 23, 2010

First Submitted That Met QC Criteria

June 23, 2010

First Posted (Estimate)

June 24, 2010

Study Record Updates

Last Update Posted (Actual)

May 28, 2019

Last Update Submitted That Met QC Criteria

May 23, 2019

Last Verified

February 1, 2014

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2009.555

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes

Clinical Trials on First period DHA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe